AR021509A1 - Derivados de benzofurano, su preparacion y uso - Google Patents

Derivados de benzofurano, su preparacion y uso

Info

Publication number
AR021509A1
AR021509A1 ARP990106110A ARP990106110A AR021509A1 AR 021509 A1 AR021509 A1 AR 021509A1 AR P990106110 A ARP990106110 A AR P990106110A AR P990106110 A ARP990106110 A AR P990106110A AR 021509 A1 AR021509 A1 AR 021509A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
indolyl
trifluoromethyl
alkenyl
Prior art date
Application number
ARP990106110A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR021509A1 publication Critical patent/AR021509A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invencion se relaciona con derivados de benzofurano que tienen la formula general (1) en donde R1 es hidrogeno, halogeno, trifluorometilo,trifluormetilsulfoniloxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, alcoxi C1-6, hidroxi, formilo, acilo, amino, alquilamino C1-6,dialquilamino C2-12, acilamino, alcoxicarbonilamino C1-6, aminocarbonilamino, alquilaminocarbonilamino C1-6, dialquilaminocarbonilamino C2-12, nitro, ciano,COOH, o COO-alquilo C1-6; R2 y R3 son cada uno independientemente seleccionados entre hidrogeno, trifluorometilo, alquilo C1-6. alquenilo C2-6, cicloalquiloC3-8 y alcoxi C1-6; n es 1, 2, 3, 4 o 5; m es 0 o 1; A es de formulas (2), (3), (4) y (5) en donde Z es O o S; s es 0 o 1; q es 0 o 1; R4 es hidrogeno,alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquil C1-6-Arilo, o alquil C1-6-O-Arilo, D es un grupo espaciador seleccionado entre alquenileno C2-6 yalquileno C2-6 recto o ramificado; B es un grupo seleccionado entre el grupo de formula (6), (7) y (8) en donde R5, R6, R7, R8,R9 y R10 son cada unoindependientemente seleccionados entre los sustituyentes R1; o R8 y R9 juntos forman un anillo de 5 o 6 miembros fusionado que opcionalmente contiene otrosheteroátomos; y el heterociclo resultante es opcionalmente sustituido con sustituyentes seleccionados entre los sustituyentes R1; o dos de los grupos de R5,R6 y R7 están unidos formando un puente -O-(CH2)p-O-, en donde p es 1 o 2: Ar y Arilo se seleccionan independientemente entre el grupo que consiste en fenilo,2-tienilo, 3-tienilo, 2-furanilo, 3-furanilo, 2-pirimidilo, 1-indolilo, 2-indolilo, 3-indolilo, 1-indol-2-onilo, 3-indol-2-onilo, 2- o 3-benzofuranilo, 2- o 3-benzotiofenilo, 1-naftilo o 2-naftilo, cada uno opcionalmente sustituido con halogeno, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, hidroxi, alquilsulfoniloC1-6, ciano, trifluorometilo, trifluorometilsulfoniloxi, cicloalquilo C3-8, cicloalquilo C3-8-alquilo C1-6, nitro, amino, alquilamino C1-6, dialquilaminoC2-12, acilamino o alquilendioxi; sus enantiomeros y sal de adicion de ácido farmacéuticamente aceptable de los mismos. Los compuestos se enlazan potentemente
ARP990106110A 1998-12-08 1999-12-01 Derivados de benzofurano, su preparacion y uso AR021509A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11136098P 1998-12-08 1998-12-08
DKPA199801631 1998-12-09

Publications (1)

Publication Number Publication Date
AR021509A1 true AR021509A1 (es) 2002-07-24

Family

ID=43768792

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106110A AR021509A1 (es) 1998-12-08 1999-12-01 Derivados de benzofurano, su preparacion y uso

Country Status (18)

Country Link
EP (1) EP1137644B9 (es)
JP (1) JP2002531556A (es)
AR (1) AR021509A1 (es)
AT (1) ATE249451T1 (es)
AU (1) AU759248B2 (es)
CA (1) CA2353618A1 (es)
CZ (1) CZ20012041A3 (es)
DE (1) DE69911243T2 (es)
DK (1) DK1137644T3 (es)
ES (1) ES2204175T3 (es)
HU (1) HUP0104510A3 (es)
IL (1) IL143082A (es)
ME (1) MEP38508A (es)
PT (1) PT1137644E (es)
RS (1) RS50065B (es)
SE (1) SE1137644T5 (es)
SI (1) SI1137644T1 (es)
WO (1) WO2000034263A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
EA008373B1 (ru) * 2000-07-07 2007-04-27 Х. Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA008372B1 (ru) * 2000-07-07 2007-04-27 Х.Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
UA75081C2 (en) 2000-07-21 2006-03-15 Lundbeck & Co As H Inhibitors of the glycine transporter, use thereof and a pharmaceutical composition based thereon
AU2001288605A1 (en) * 2000-09-06 2002-03-22 Chugai Seiyaku Kabushiki Kaisha A traceless solid-phase synthesis of 2-imidazolones
US7235569B2 (en) 2003-05-02 2007-06-26 Wyeth Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
US7276603B2 (en) 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (es) * 1965-03-18
GB1173312A (en) * 1966-03-17 1969-12-10 Kefalas As Heterocyclic Compounds
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
CN1046507C (zh) * 1993-12-28 1999-11-17 法玛西雅厄普约翰美国公司 用于治疗中枢神经系统和心血管疾病的杂环化合物
ZA954689B (en) * 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines

Also Published As

Publication number Publication date
DE69911243D1 (de) 2003-10-16
ATE249451T1 (de) 2003-09-15
AU759248B2 (en) 2003-04-10
CZ20012041A3 (cs) 2001-10-17
IL143082A0 (en) 2002-04-21
EP1137644B1 (en) 2003-09-10
HUP0104510A3 (en) 2003-01-28
WO2000034263A1 (en) 2000-06-15
JP2002531556A (ja) 2002-09-24
SI1137644T1 (en) 2003-12-31
YU38401A (sh) 2005-06-10
DK1137644T3 (da) 2003-12-08
DE69911243T2 (de) 2004-07-15
SE1137644T5 (es) 2004-05-11
AU1503600A (en) 2000-06-26
SE1137644T3 (es) 2003-12-02
ES2204175T3 (es) 2004-04-16
PT1137644E (pt) 2004-01-30
HUP0104510A2 (hu) 2002-04-29
EP1137644B9 (en) 2004-03-17
MEP38508A (en) 2011-02-10
RS50065B (sr) 2009-01-22
CA2353618A1 (en) 2000-06-15
EP1137644A1 (en) 2001-10-04
IL143082A (en) 2004-06-20

Similar Documents

Publication Publication Date Title
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
RS50045B (sr) Aktivatori glukokinaze
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
DE60204674D1 (de) Retinoid x rezeptormodulatoren
DK0628311T3 (da) Xanthinderivater som antidepressive midler
DE69710319D1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
HRP20000854B1 (en) Therapeutic biaryl derivatives
AR049116A1 (es) Derivados de piperazina y usos para controlar pestes.
AR021509A1 (es) Derivados de benzofurano, su preparacion y uso
FI952709A (fi) 1,4-bentsodiatsepiinijohdannaisia ja niiden käyttö cck-modulaattoreina
DK1034174T3 (da) Azaringetherderivater og disses anvendelse som nikotin-ACh-receptormodulatorer
EA200101181A1 (ru) Циклотиокарбаматные производные в качестве модуляторов рецептора прогестерона
DE69125811D1 (de) Verfahren zur Herstellung substituierter Benzofuranderivate
DE60002583D1 (de) Benzofurylpiperazine als serotonin-agonisten
PT1057827E (pt) Derivados da espiropiperidina
ES2086090T3 (es) Derivados de 4-pirimidinas, su preparacion y su aplicacion en terapeutica.
SG164268A1 (en) Quinolin-4-yl derivatives i
DK349287D0 (da) (2-dimethylamino-ethyl)(2-((2-methylthio-phenyl)(phenylmethyl)amino)-2-oxo-ethyl)carbamater eller urinstofderivater, fremgangsmaade til fremstilling og anvendelse som laegemiddel af saadanne forbindelser
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.
CO4950554A1 (es) Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
ES517042A0 (es) Procedimiento para la preparacion de una aroilimidazolidin-2-ona.
AR002259A1 (es) Derivados de 1-oxo-2-(fenilsulfonilamino)pentilpiperidina, su preparacion, compuestos intermedios y composicion que contiene a dichos derivados.
AR015034A1 (es) Derivados de indolilo, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure